A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1836-1844

  Hu, Zhiming ^a,b   Tan, Wanlong ^b   Zhang, Lin ^a   Liang, Zhongkun ^b   Xu, Cuixiang ^b   Su, Hua ^a   Lu, Jianxin ^a,b   Gao, Jimin ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biotinylation; Fusion protein; GM CSF; Immunotherapy; Streptavidin; Superficial bladder cancer

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMOBILIZED PROTEIN;

ANIMAL; ARTICLE; BLADDER TUMOR; C57BL MOUSE; CHEMISTRY; FEASIBILITY STUDY; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOUSE; PROTEIN FOLDING; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ANIMALS; FEASIBILITY STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMOBILIZED PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; PROTEIN FOLDING; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

MUS;

EID: 77955157001     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00818.x     Document Type: Article

References (20)

1. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008, 179:53-6.
2. Alexandroff AB, Jackson AM, O'Donnell MA. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999, 353:1689-94.
3. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002, 188:147-54.
4. Wu Q, Mahendran R, Esuvaranathan K. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin Cancer Res. 2003, 9:4522-8.
5. Wu Q, Esuvaranathan K, Mahendran R. Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter. Clin Cancer Res. 2004, 10:6977-84.
6. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther. 2003, 10:501-8.
7. Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M. Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther. 2004, 4:1595-607.
8. Murphy A, Westwood JA, Teng MW. Gene modification strategies to induce tumor immunity. Immunity. 2005, 22:403-14.
9. Sano T, Cantor CR. Streptavidin-containing chimeric proteins: design and production. Methods Enzymol. 2000, 326:305-11.
10. Goldenberg DM, Sharkey RM, Paganelli G. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006, 24:823-34.
11. Sternberg CN, Arena MG, Pansadoro V. Recombinant tumor necrosis factor for superficial bladder tumors. Ann. Oncol. 1992, 3:741-5.
12. Sarosdy M. High-dose versus low-dose intravesical interferon-α2b in the treatment of carcinoma in situ: a randomized, controlled study. Anticancer Drugs. 1992, 1:13-7.
13. Hermann GG, Geertsen PF, Von der Maase H. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res. 1992, 52:726-33.
14. Stravoravdi P, Toliou T, Kirtsis P. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. Interferon Cytokine Res. 1999, 19:221-5.
15. Gao J, Huang S, Li M. GM-CSF- modified mouse B16.F10 melanoma whole cell vaccine. Vaccine. 2006, 24:5265-8.
16. Loskog A, Ninalga C, Paul-Wetterberg G. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007, 177:353-8.
17. Loskog A, Dzojic H, Vikman S. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol. 2004, 172:7200-5.
18. Liakou CI, Narayanan S, Ng Tang D. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007, 7:10.
19. Paganelli G, Grana C, Chinol M. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999, 26:348-57.
20. Meredith RF, Buchsbaum DJ. Pretargeted radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2006, 66:S57-9.